Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 323-327

  Iacovelli, R ^a   Altavilla, A ^a   Procopio, G ^b   Bracarda, S ^c   Santoni, M ^d   Cascinu, S ^d   Cortesi, E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c USL 8   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Abiraterone acetate; Cabazitaxel; Castration resistant prostate cancer; Enzalutamide; Performance status; Second line

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PREDNISONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PUBLICATION BIAS; TAXOIDS; TREATMENT OUTCOME;

EID: 84887609351     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.20     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts & Figures, 2012American Cancer Society: Atlanta, Georgia, USA.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
4. Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campenn? GM et al. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther 2012; 13: 1001-1008.
5. Paoli CJ, Bach BA, Tsai KT, Wong B. A retrospective study of performance status in oncology patients at diagnosis and over the first year in routine clinical practice. J Clin Oncol 2011; 29: (suppl; abstr e16521).
6. Oosterlinck W, Mattelaer J, Derde MP, Kaufman L. Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients. Acta Urol Belg 1995; 63: 1-9.
7. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26: 2544-2549.
8. Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64: 300-306.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
12. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J 1988; 296: 1313-1316.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-560.
14. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
17. Review Manager (RevMan) [Computer program]. Version 5.2. The Nordic Cochrane Centre. The Cochrane Collaboration. Copenhagen, 2012.
18. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-5438.
19. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
20. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012; 13: 983-992.
21. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
22. Morabito A, Gebbia V, Di Maio M, Cinieri S, Vigano MG, Bianco R et al. Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. Lung Cancer 2013; 81: 77-83.
23. Zukin M, Barrios CH, Rodrigues Pereira J, De Albuquerque Ribeiro R, de Mendonca Beato CA, do Nascimento YN et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced nonsmall cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013 (Epub ahead of print).
24. Jouveshomme S, Canoui-Poitrine F, Le Thuaut A, Bastuji-Garin S. Results of platinumbased chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study. Med Oncol 2013; 30: 544-553.
25. National Comprehensive Cancer Network. Prostate Cancer. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed on 20 January 2012.
26. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
27. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
28. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castrationresistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217.
29. Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2012; 24(4): 1017-1025.
30. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
31. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.